Oncologists Satisfaction With Outcomes of Some Cytotoxic Agents

NCT ID: NCT02630979

Last Updated: 2017-03-28

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-11-30
• Study Completion Date: 2017-12-31

Brief Summary

The study measures the degree of oncology physician satisfaction with the outcomes of some cytotoxic agents.

Detailed Description

This is a prospective observational questionnaire based study measuring the degree of satisfaction of medical oncologists with the results of some expensive cytotoxic agents. The study also measures the physician knowledge with the toxicity profile of the tested drugs, pharmaceutical perspectives, methods of administration, adherence to guidelines and the degree of bias of the physicians when prescribing this drugs.

The tested drugs are trastuzumab, lapatinib, sunitinib, m tor inhibitors, sorafenib, cetuximab, panitumumab, bevacizumab, erlotinib, rituximab, imatinib mesylate, gefitinib, abiraterone acetate, cabazitaxel, pertuzumab, fulvestrant, pemetrexate and crizotinib.

The evaluation will be through a predesigned questionnaire ( 30 questions ). The questions are divided into four categories measuring four items, the degree of physician satisfaction with the drugs results and toxicity profile, orientation with pharmaceutical perspectives of the drugs, adherence to guidelines and degree of bias with pharmaceutical companies complements. A predesigned questionnaire based scoring system will categorise the processed data to low, intermediate and high score for each of the four measured topics. The data will be processed and the degree of satisfaction, orientation with pharmaceutical perspectives, adherence to guidelines and degree of bias will be grade to low, moderate or high. Subsequent recommendations for cost effective analysis, physician education and strict auditing measures for drug prescription will be elaborated for the drugs.

NB: The study will be on two waves. The first wave will evaluate 9 drugs and the second wave will evaluate 8 drugs.

Conditions

Physician Satisfaction With the Outcomes of Cytotoxic Drugs

Study Design

• Observational Model Type: ECOLOGIC_OR_COMMUNITY
• Study Time Perspective: PROSPECTIVE

Study Groups

No treatment

Clinical and medical oncology physicians.

Measuring satisfaction, knowledge and bias

Intervention Type: BEHAVIORAL

Questionnaire based assessment.

Interventions

Measuring satisfaction, knowledge and bias

Questionnaire based assessment.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Physicians ranked from senior resident to professional consultants

Exclusion Criteria

• Junior residents.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ain Shams University

OTHER

Sponsor Role: lead

Responsible Party

Mahmoud Ellithy

Associate professor of clinical oncology. Ain Shams University

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mahmoud Ellithy, Consultant

Role: PRINCIPAL_INVESTIGATOR

Faculty of Medicine. Ain Shams University

Noha Salaheldin elbogdady, Pharmaciest

Role: STUDY_DIRECTOR

Misr university

Locations

Faculty of Medicine. AIn Shams University

Cairo, Elabbasia, Egypt

Site Status: RECRUITING

Countries

Egypt

Central Contacts

Mahmoud Ellithy, Consultant

Role: CONTACT

ellithym@med.asu.edu.eg

01000069694 ext. 002

Lamiaa Elwakil, Pharmaciest

Role: CONTACT

lamywak@yahoo.com

01005201099

Facility Contacts

Mahmoud Ellithy, Consultant

Role: primary

ellithym@med.asu.edu.eg

01000069694 ext. 002

Lamiaa Elwakil, Pharmaciest

Role: backup

lamywak@yahoo.com

01005201099 ext. 002

Other Identifiers

Cure and more1

Identifier Type: -

Identifier Source: org_study_id